Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

VL422

  Cat. No.:  DC65850   Featured
Chemical Structure
2765519-47-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86 21 58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
VL422 is a novel ionizable cationic lipid, as a high-performance "molecular engine" for next-generation Lipid Nanoparticles (LNPs), specifically engineered for the precise delivery of CRISPR base editors and mRNA. Its sophisticated chemical architecture is designed to remain neutral in systemic circulation for enhanced safety, while rapidly protonating within the acidic cellular environment to trigger efficient endosomal escape and cargo release. Validated by groundbreaking research in liver-targeted gene silencing, VL422 has become a critical benchmark molecule for developing permanent, transformative therapies for cardiovascular and metabolic diseases.
Cas No.: 2765519-47-7
Chemical Name: VL422
Synonyms: octanedioic acid, 1,1′-[2-[[[[3-(diethylamino)propoxy]carbonyl]oxy]methyl]-1,3-propanediyl] 8,8′-bis(1-octylnonyl) ester,VL-422, VL 422
SMILES: CCCCCCCCC(CCCCCCCC)OC(CCCCCCC(OCC(COC(OCCCN(CC)CC)=O)COC(CCCCCCC(OC(CCCCCCCC)CCCCCCCC)=O)=O)=O)=O
Formula: C62H117NO11
M.Wt: 1052.6
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication: Rajeev, K.G., Biswas, S., Kasiewicz, L.N., et al. Lipid formulations for gene editing. 1-312 (2022).
Cat. No. Product name Field of application
DC65850 VL422 VL422 is a novel ionizable cationic lipid, as a high-performance "molecular engine" for next-generation Lipid Nanoparticles (LNPs), specifically engineered for the precise delivery of CRISPR base editors and mRNA. Its sophisticated chemical architecture is designed to remain neutral in systemic circulation for enhanced safety, while rapidly protonating within the acidic cellular environment to trigger efficient endosomal escape and cargo release. Validated by groundbreaking research in liver-targeted gene silencing, VL422 has become a critical benchmark molecule for developing permanent, transformative therapies for cardiovascular and metabolic diseases.
X